Curriculum Vitae
Latest Update: October 2000
Buck A. Rhodes, Ph.D. President
Buck A. Rhodes Biomedical Consulting and Hypnotherapy, Inc.
1005 Franciscan NE,
Albuquerque, New Mexico, U.S.A.
Radiopharmacologist, Hypnotist and Consultant
Phone 505 765-1147, home 505 244-0777
EDUCATION:
New Mexico State University
New Mexico State University
U.S.P.H.S. Div. Radiol. Sciences
The Johns Hopkins University
The Alchemical Institute
B.S. (honors)
Graduate studies
In service training
Ph.D.
Master Hypnotist
1958
1960
1962
1966
1997
Agronomy
Chemistry
Radiation Safety
Radiological Science
Hypnotherapy
RESEARCH AND PROFESSIONAL EXPERIENCE:
1960-62
1962-66
1966-75
1975-76
1976-81
1981-85
1985-96
1996-
1999-
Chemist, commissioned Corp. US PHS, Division of Radiological Science;
Assigned to Cincinnati, OH and Farmington, NM
Graduate Student and Graduate Assistant, The Johns Hopkins University
Instructor, Assistant Professor, Associate Professor (Radiology and
Radiological Science, The Johns Hopkins School of Medicine, Hygiene
and Public Health
Professor of Pharmacy and Radiology, Director of Radiopharmacy,
University of Kansas Medical Center, Kansas City, KS
Professor of Pharmacy and Radiology, Directory of Radiopharmacy,
University of New Mexico, Albuquerque, NM
Senior Vice President for Scientific Affairs, Summa Medical Corporation,
Albuquerque, NM
President and Founder, RhoMed Incorporated, Albuquerque, NM
President and Founder, Buck A. Rhodes Biomedical Consulting and
Hypnotherapy Inc. (dba Buck Inc.), Albuquerque, NM Federal Tax ID #
85 044 2075. 1005 Franscisan NE, Albuquerque, NM 87102 ph 505 7651147
Consultant to Dean of the UNM College of Pharmacy
HONORS AND RESPONSIBILITIES
Board Member, Society of Nuclear Medicine
Board Member and Chairman of the Examination Committee, American Board of
Science in Nuclear Medicine
Honorary Diplomat, American Board of Science in Nuclear Medicine
Honorary Member, El Colegio Internacional De Medicos Nucleares A.C.
BIOGRAPHICAL SUMMARY
Dr. Rhodes has served consultant to the International Atomic Energy
Commission, and to a number of businesses such as 3M Company, Abbott Laboratories,
etc. He has organized, chaired or co-chaired five international meetings. He has
published about 200 scientific papers, 7 textbooks, and 8 audiovisual programs. He is
inventor or co-inventor on 20 U.S. patents and numerous foreign patents. He has served
as principal investigator for grants and contracts totaling over $5,000,000. He has
prepared and submitted several Investigational New Drug (IND) applications with the
U.S. Food and Drug Administration. Currently, a monoclonal antibody-based drug he
invented for abscess imaging is awaiting approval before the U.S. FDA.
Starting before completing his Ph.D. degree in 1966, Dr. Rhodes became a faculty
member in Radiological Sciences and Radiology at The Johns Hopkins University. Here
he was involved in the development and testing of new radioactive drugs, under the
direction of Dr. Henry N. Wagner, Jr. He was also involved in quality control test
development and development of new applications for radioactive drugs. Another aspect
of his work was trouble shooting of adverse reactions. Dr. Rhodes was promoted to the
level of Associate Professor by the time of his departured Hopkins.
Dr. Rhodes was then appointed as Professor of Pharmacy and Radiology, and
Director of Radiopharmacy, first at the University of Kansas and then at the University of
New Mexico. He coauthored the first textbook in Radiopharmacy with Dr. Barbara
Howard. As Director of The University of New Mexico Radiopharmacy, he was
responsible for the formulation, distribution, marketing, customer relations, radiation
safety, budgetary management and quality control of radiopharmaceuticals throughout
the State of New Mexico including some sites in Texas and Mexico. Graduates of this
program became leaders in the field and instituted commercial radiopharmacies
nationally and internationally. He introduced the subject of clinical radiopharmacy at
UNM, including the basic principles of clinical trial management. Another innovation
was the use of video feedback in the training of pharmacists in giving cases reports
before audiences.
Dr. Rhodes joined industry in 1981, first as Senior Vice President for Scientific
Affairs of Summa Medical Corporation and then as Co-Founder and President of
RhoMed Inc. In 1996, Dr. Rhodes retired as President of RhoMed Inc. continuing to
serve the company as a consultant for two additional years. During this time he
organized Buck A. Rhodes BioMedical Consulting and Hypnotherapy Inc. Dr. Rhodes is
a trained and certified Hypnotherapist.
Dr. Rhodes has taught Radiopharmacy to technicians, physicians, scientists, and
pharmacists. He co-authored the chapter on radiopharmaceuticals in Dr. Wagner’s first
text book in Nuclear Medicine and introduced the word: radiopharmaceutical. Dr.
Rhodes also chaired the Subcommittee on Adverse Reactions to Radiopharmaceuticals
and edited the first textbook on quality control in nuclear medicine.
Research interests have focused on formulations radiolabeled with I-123, Tc-99m,
Re-186 and In-113m. In 1976, he began developing radiolabeled antibodies as diagnostic
tracers and later worked with radiolabeled peptides. Many of the newly discovered
radiopharmaceuticals become subject of patents in the U.S. and abroad.
SAMPLE PUBLICATIONS: (this list is selected from some 200 publications)
1.
7.
11.
15.
17.
29.
35.
36.
37.
38.
62.
101.
108.
111.
114.
118.
125.
143.
Rhodes BA: Liquid scintillation counting of radioiodine. Anal. Chem.
37:995-997, 1965.
Wagner HN Jr, Rhodes BA: The Radiopharmaceutical. In: Prinicples of
Nuclear Medicine, HN Wagner Jr. (ed.). Philadelphia, WB Saunders Co.,
1968; pp 259-301
Rhodes BA, Zolle I, Buchanan, Wagner HN Jr: Radioacrtive microspheres
for studies of the pulmonary circulation. Radiology 92: 1453-1460, 1969.
Strauss HW, Hurley PJ, Rhodes BA, Wagner HN Jr: Quantification of rightto-left transpulmonary shunts in man. J. Lab, Clin. Med. 74: 597-607, 1969.
Rhodes BA, Wagner HN Jr: Radiation physics. In: The Thryoid. SC Wermer
(ed.) NY, Harper & Row, 1971. pp 163-184.
Rhodes BA: Low probability of allergic reaction to albumin microspheres.
Letter-to-the-editor. J. Nucl. Med. 12:649-650, 1971.
Pavoni P, Moen T, Rhodes BA, Wagner HN Jr: Changes in Xe-133
clearances resulting from electrically induced muscle contractions. II. Study
in man. J. Nucl. Biol. Med. 15:19-20, 1971.
Wagner HN Jr, Rhodes BA: Radioactive tracers in the diagnosis of
cardiovascular disease. Progress in Cardiovasc. Dis. 15:1-24, 1972.
Rhodes BA, Greyson ND, Siegel ME, Giargiana FA Jr., White RI, Williams
GM, Wagner HN Jr: The distribution of radioactive microspheres after intraarterial injection in the legs of patients with peripheral vascular disease.
Amer. J. Roentgenology, Radium Therapy & Nucl. Med. 118:814-819, 1973.
Rhodes BA, Kamanetz GS, Wagner HN Jr: The use of limulus testing to
reduce the incidence of adverse reactions to cisternographic agents.
Neurology 24:810-12, 1974.
Chen M, Rhodes BA, Larson SM, Wagner HN Jr: Sterility testing of
radiopharmaceuticals. J. Nucl. Med. 15:1142-1144, 1974.
Ford L, Schroff A. Benson W. Atkins H. Rhodes BA: SNM drug problem
reporting systm. J. Nucl. Med. 19:116-117, 1978.
Hladik WB III, Friedman BE, Adams RF, Rhodes: Instruction in
radiopharmacy – a clinical approach. Amer. J. Pharm. Educ. 43: 27-31, 1979.
Rhodes BA: Teaching pharmacists to communicate well: Amer. Druggist,
Nov. 1979, p 89.
Rhodes BA, Cordova MA: Adverse reactions to radiopharmaceuticals:
Incidence in 1978 and associated symptoms. J. Nucl. Med. 21:1107-1110,
1980.
Rhodes BA. Torvestad DA, Breslow K, Burchiel SW, Austin RK: A kit for
direct labeling of antibody and antibody fragments with Tc-99m. J. Nucl.
Med 21:54, 1980.
Hladik WB III,Nigg KK, Rhodes BA: Drug induced changes in the biologic
distribution of radiopharmaceuticals. Sem. Nucl. Med. 12:184-218, 1982.
Rhodes BA, Zamora PO, Newell KD, Valdez E: technetium-99m labeling of
murine monoclonal antibody fragments. J. Nucl. Med., April 1986.